Wang Shifang, Desikan Sai Prasad, Jeffrey Jay, McClain Charles, Desikan Raman
White River Health System Batesville Arizona USA.
EJHaem. 2020 May 31;1(1):309-311. doi: 10.1002/jha2.21. eCollection 2020 Jul.
Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patients achieving major molecular response at an earlier time point. Asymptomatic elevations in pancreatic enzyme is common and acute pancreatitis within weeks to months from start of therapy has been observed. Delayed onset pancreatitis has not been reported. We report a case of delayed onset pancreatitis in a patient with sustained complete molecular response. On account of the deep response, we were able to avoid starting alternate tyrosine kinase inhibitors that could also result in pancreatitis as a class effect.
酪氨酸激酶抑制剂（TKI）的出现彻底改变了慢性髓性白血病的治疗方法。伊马替尼是首个用于治疗慢性粒细胞白血病（CML）的药物。第二代TKI尼罗替尼能使更多患者在更早的时间点达到主要分子反应。胰腺酶无症状升高很常见，且在开始治疗后的数周或数月内已观察到急性胰腺炎。延迟性胰腺炎尚未见报道。我们报告一例处于持续完全分子反应的患者发生延迟性胰腺炎的病例。鉴于该患者的深度反应，我们得以避免启用可能因类效应导致胰腺炎的其他酪氨酸激酶抑制剂。
